After TauRx Pharmaceutics’ investigational Alzheimer’s treatment hydromethylthionine mesylate (HMTM) was found to slow the disease’s progression it could, if approved, become the first oral treatment targeting the tau protein.
28 April 2025
Germany, France, Belgium, Italy and the Netherlands account for the majority of trade in pharmaceutical products across Europe, according to a new report.
28 April 2025
Global temperature-sensitive packing and digital solutions provider Cold Chain Technologies (CCT) has acquired Australia's Global Cold Chain Solutions (GCCS) to expand its Asia Pacific presence and capabilities.
28 April 2025
21GRAMS and Havas Lynx lead the charge at the PM Society Awards for pharma marketing and healthcare communications
28 April 2025
Tina Backhouse from Theramex on the treatment access challenges women face
28 April 202521GRAMS and Havas Lynx lead the charge at the PM Society Awards for pharma marketing and healthcare communications
28 April 2025
From prostate cancer to hormonal health, many areas of men’s health require more attention. As male life expectancy and healthy lifespan continue to lag behind, Charlie Bryant at Androlabs explores how pharma could help improve this by shifting its focus from treatment to prevention
28 April 2025Tina Backhouse from Theramex on the treatment access challenges women face
28 April 2025
Dr Werner Engelbrecht at Veeva Systems discusses how compliance can be turned into a competitive advantage with connected platforms and data, AI-driven efficiencies and new patient-centric models
28 April 2025
Ruthie Davi and Elizabeth Lamont at Medidata AI discuss how adopting different approaches, such as synthetic control arms and remote monitoring, can aid researchers in investigating rare diseases.
12 February 2025
Vikas Jain at Tata Consultancy Services examines three key avenues for AI to be adopted by the pharma industry and the benefits that each adoption can have.
12 February 2025
Two biotech firms and a radiochemistry company will develop next-generation targeted alpha-therapies to treat various forms of cancer.
Belgium biotechnology company Galapagos has made changes at the top as it prepares to split into two separate entities.
Nuclear medicine company Curium Pharma has acquired Monrol (Eczacıbaşı-Monrol Nuclear Products) to expand its presence in the sector.
Finnish health and social care provider Mehiläinen has agreed to acquire Eastern European healthcare companies Regina Maria and MediGroup.
Global temperature-sensitive packing and digital solutions provider Cold Chain Technologies (CCT) has acquired Australia's Global Cold Chain Solutions (GCCS) to expand its Asia Pacific presence and capabilities.
Business and technology consultancy HERAX Life Science has been acquired by ProductLife Group (PLG).
3M spin-off Solventum has announced that global supplier of analytical instruments Thermo Fisher Scientific has agreed to purchase its purification and filtration businesses unit for $4.1bn.
Northern Irish biostatistics and data science company, Exploristics, has announced that it has been acquired by MMS.
CANDOR Biosciences, a supplier in immunoassay solutions, has been acquired by Medix Biochemica, a supplier of raw materials for in vitro diagnostics (IVD). This will support the vision from Medix Biochemica to become the first-in-choice partner for raw materials in the IVD industry.
Subsidiary of Molex, Phillips Medisize, has announced the successful acquisition of Vectura Group Ltd. The acquisition was completed through an affiliate.
A division of European specialty generics platform Stragen Group, Stragen Services, has been acquired by ProductLife Group (PLG), a global consulting services specialising in areas around scientific, regulatory, compliance and digital transformation.
Infrareal holding has announced that it has entered into a corresponding transfer agreement with Takeda to acquire the 24-hectare site in Orth, Lower Austria – subject to merger control approval from Austrian regulators.
Global leader in R&D sample stability and biorepository storage Astoriom has announced the acquisition of both MTS Cryo stores and Cool Repair Scientific UK (both Nottingham, UK).
Earlier this year, Axol Bioscience announced the acquisition of Phenocell SAS with the goal of expanding cell models and services to include dermatology and ophthalmology.
The CDMO launched earlier this year at the CPHI conference in Milan, Italy.
Kynos Therapeutics – a Scottish clinical stage biopharma company focusing on developing novel kynurenine 3-monooxygenase (kmo) inhibitors – has been acquired by Dr. Falk Pharma.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Moderna’s plans to manufacture commercial mRNA vaccines at its existing facility in Harwell in Oxfordshire.
UK News, 28 April 2025
Besins Healthcare has launched in the UK its new treatment, based on progesterone, to prevent miscarriage.
UK News, 28 April 2025
The Scottish Medicines Consortium (SMC) has approved Ipsen’s Iqirvo (elafibranor) in NHS Scotland to treat the rare liver disease primary biliary cholangitis (PBC).
UK News, 28 April 202521GRAMS and Havas Lynx lead the charge at the PM Society Awards for pharma marketing and healthcare communications
UK News, 28 April 2025Japan-based biopharmaceutical company Takeda has announced the launch of its Conceptual Implementation Framework to address barriers such as cost-effectiveness relating to combination treatment introduction in the UK.
UK News, 25 February 2025Besins Healthcare has launched in the UK its new treatment, based on progesterone, to prevent miscarriage.
San Diego-headquartered biotechnology company GRI Bio has strengthened its global intellectual property portfolio with the addition of two new patents.
Japan’s Ministry of Health, Labour and Welfare has authorised the marketing and manufacturing of Sanofi and Regeneron’s chronic obstructive pulmonary disease (COPD) treatment Dupixent (dupilumab).
US regulators have granted a fast track designation to Sanofi’s mRNA chlamydia vaccine, putting it in line for development benefits and an expedited review.
The Scottish Medicines Consortium (SMC) has approved Ipsen’s Iqirvo (elafibranor) in NHS Scotland to treat the rare liver disease primary biliary cholangitis (PBC).
The European Commission (EC) has approved acoramidis to treat wild-type or variant transthyretin amyloidosis in adults with cardiomyopathy (ATTR-CM), according to an announcement from the drug’s developer BridgeBio Pharma.
The US Food and Drug Administration (FDA) has approved Samsung Bioepis’ biosimilars referencing Amgen’s bone disease therapy denosumab.
UCB’s Fintepla (fenfluramine) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged two years and older.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Telix Pharmaceuticals’ imaging agent Illuccix (gozetotide) for use in adult prostate cancer patients who are undergoing a position emission tomography (PET) scan.
Johnson & Johnson company Janssen-Cilag Interenational NV has announced news that the European Commission (EC) has approved a marketing authorisation for the combination of LASCLUZE (lazertinib) and RYBREVANT (amivantamab) for first-in-line treatment of adult patients with epidermal growth factor receptor (EGFR) mutations exon 19 deletions (ex19del) or exon 21 L858R (L858R) substitution mutations in non-small cell lung cancer (NSCLC).
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to ANDEMBRY (garadacimab) by CSL for the prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients over the age of 12.
Santhera Pharmaceuticals has received positive final guidance from the National Institute for Care and Excellence (NICE) for AGAMREE (vamorolone) to be used as treatment of Duchenne Muscular Dystophy (DMD) in patients who are aged 4 or older in the UK.
BALVERSA (erdafitinib) has been granted marketing approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of the most common type of bladder cancer, metastatic or unresectable urothelial carcinoma.
Theramex, a dedicated women’s health company, has announced that the Scottish Medicines Consortium (SMC) has recommended YSELTY (linzagolix) for the treatment of moderate or severe symptoms of uterine fibroids (UFs) in adult women of reproductive age.
Approval of an updated version of the Nuvaxovid COVID-19 vaccine, developed by Novavax, has been granted by the Medicines and Healthcare products Regulatory Agency (MHRA), to target the omicron JN.1 COVID-19 subvariant.
Earlier in November, Johnson & Johnson Innovative Medicine have applied to the US Food and Drug Agency (FDA) and the European Medicines Agency (EMA) for the approval of a new indication for DARZALEX FASPRO (daratumumab and hyluronidase-fihj).
After TauRx Pharmaceutics’ investigational Alzheimer’s treatment hydromethylthionine mesylate (HMTM) was found to slow the disease’s progression it could, if approved, become the first oral treatment targeting the tau protein.
Two biotech firms and a radiochemistry company will develop next-generation targeted alpha-therapies to treat various forms of cancer.
Belgium biotechnology company Galapagos has made changes at the top as it prepares to split into two separate entities.
Germany, France, Belgium, Italy and the Netherlands account for the majority of trade in pharmaceutical products across Europe, according to a new report.
EDX Medical – a clinical diagnostics company founded by Sir Christopher Evans, OBE – has announced the development of a new ‘super test’ for prostate cancer.
Global pharma company Thermo Fisher Scientific has announced the launch of CorEvitas Adolescent Alopecia Registry, which aims to address an unmet need in the research for adolescent alopecia.
To mark last month’s World Cancer Day, a new plan was unveiled by the UK Government to help tackle the impact of cancer across England.
Moderna, a US-based biopharmaceutical company with an expertise in messenger RNA (mRNA), has announced updates in the two years since it signed a ten-year partnership with the UK Government.
Private medical device and artificial intelligence (AI)-led company, BrightHeart, has revealed two studies which show an improvement to pre-natal care through the use of AI technology which received clearance from the US Food and Drug Administration (FDA) in November 2024.
The University of Sheffield, UK, has announced study results for its trial into the survival rates of patients with operable bladder cancer, finding that those who have immunotherapy before and after the surgery have significantly improved rates of survival.
The European Commission (EC) has announced the opening of a new Biotech and Biomanufacturing Hub, supporting start-ups and small-to medium-sized enterprises (SMEs) in bringing new innovations to the EU market.
US-based pharmaceutical company Alvogen has issued a voluntary recall of one batch of its Fentanyl Transdermal System 25mcg/h transdermal patches, amid concerns that patches could be multi-stacked in a single product pouch.
HUTCHMED has announced that the China National Medical Products Administration (NMPA) have granted a priority review for a new drug application (NDA).
SolasCure, a biotechnology company that is dedicated to working towards filling the current market gap in debridement – the removal of necrotic tissue to encourage healing – and healing solutions for chronic wounds has announced a partnership with the US Army’s Institute of Surgical Research (USAISR).
The HFX iq, a personalised spinal cord stimulation (SCS) system developed by Nevro that leverages artificial intelligence technology to manage chronic pain, has received CE mark certification in Europe.
Earlier in November, the Chalmers University of Technology in Sweden published the results of a study demonstrating that resistant bacteria, when paired with material equipped with antibacterial peptides, can regain susceptibility to antibiotics.
Pharmafocus April/May 2025, which arrives at a time when established scientific and trade norms are being upended under the current US administration. Including European Pharma trade report, upcoming European biotechnology law and new Artificial Intelligence Act, men’s health, menopause care and mental health
Welcome to Pharmafocus March 2025! Read on for a newsletter featuring insights into women's health, a COVID-19 retrospective and more!
Pharmafocus January +February 2025 Edition
Welcome to the final edition of 2024: Pharmafocus December.
Welcome to Pharmafocus November 2024!
Welcome to the October 2024 edition of Pharmafocus!
Welcome to the September 2024 issue of Pharmafocus! This issue covers the latest news including new FDA approval for primary biliary cholangitis, NICE recommendations for skyrizi (risankizumab), CHMP opinion on Merck’s KEYTRUDA, as well as articles on precision medicine and oral peptides PLUS what to look out for at this year's CPHI in Milan!
Welcome to the July/August 2024 issue of Pharmafocus!
Welcome to the June 2024 issue of Pharmafocus!
Welcome to the May 2024 issue of Pharmafocus!
Welcome to the April 2024 issue of Pharmafocus!
Welcome to the March 2024 issue of Pharmafocus!
Welcome to the first Pharmafocus of 2024!
Ellab has appointed Gergely Sved as its new chief executive officer (CEO) following the departure of Ludvig Enlund.
Swedish biotechnology company Asgard Therapeutics has appointed Shane Olwill as chief development officer (CDO) to further its work on in vivo direct cell reprogramming for cancer immunology.
Berlin-based ProBioGen has appointed its former chief operating officer (COO) Alfred Merz to be its new chief executive officer (CEO), a role he had previously been holding on an interim basis.
AAX Biotech has made two key appointments as it seeks to further develop its research efforts and business presence.
CluePoints has appointed Usama Dar as its new chief product and technology officer.
UK-based consultancy-led organisation Coronado Research has announced that it has appointed Gary Lyons as executive vice president (EVP) for medical affairs.
ViCentra, a company focused on its automated insulin delivery system, has announced the appointment of Tom Arnold as chief executive officer.
Eleva, a clinical-stage biopharmaceutical company, has announced the appointment of Martin Bauer as its new chief medical officer.
Novo Nordisk has announced the appointment of Sebnem Avsar Tuna as general manager for its UK affiliate.
Glox Therapeutics, a precision medicine company spun out from the Universities of Oxford and Glasgow, has announced the appointments of Michael Murray (pictured) as chair of the board and Nel Moore as scientific advisory board member.
Sapio Sciences, a provider of lab informatics solutions, has announced the appointment of Mike Hampton as chief commercial officer and unveiled its new scientific office.
Nuclera has announced the appointment of Seth Benson as its new chief financial officer, following the strengthening of its leadership team with three key appointments at the end of last year.
The International Drug Development Institute (IDDI) has announced changes to its executive leadership team to strengthen the company’s leadership and operational capabilities.
David Loose has been appointed as chief executive officer of Essex Management, part of contract research organisation Emmes Group.
Vect-Horus, a private biotechnology company specialising in molecular development, has announced the appointment of Jérôme Berger to its board of directors.
PrecisionLife has appointed seasoned executive Bill Keating as chief commercial officer of Diagnostics and Healthcare to drive commercial strategy for precision medicine.
Pharmaceutical Industry news, analysis and insights